Ongoing Clinical Trials for Recurrent Pancreatic Carcinoma
There is currently 1 ongoing clinical trial for patients with recurrent pancreatic carcinoma. This trial is testing a new investigational drug called DS-3939a in patients with advanced or metastatic solid tumors, including pancreatic cancer. The study is being conducted across multiple locations in Europe, including France, Spain, and Belgium.
Clinical trial locations
- Belgium
- France
- Spain
Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors
This clinical trial is testing a new investigational treatment called DS-3939a for patients with advanced or metastatic solid tumors, including recurrent pancreatic cancer. DS-3939a is an experimental medication given through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein.
Main inclusion criteria:
- You must have a confirmed diagnosis of locally advanced, metastatic, or unresectable cancer, which may include pancreatic cancer
- Your cancer must be measurable based on standard criteria called RECIST V1.1
- Your heart must be functioning well, with a left ventricular ejection fraction of at least 50%
- You must have adequate organ function, meaning your organs are working well enough to participate
- Your performance status must be 0 or 1 on the Eastern Cooperative Oncology Group scale, which means you are fully active or have some symptoms but can carry out light work
- For the second part of the study, your cancer must have progressed during or after your most recent treatment
- You must be able to provide a tumor sample for analysis
Main exclusion criteria:
- You must be within the specified age range for the study
- Pregnant women or those unable to provide informed consent cannot participate
- You cannot participate if you do not meet the safety and tolerability requirements for DS-3939a
Main focus and goal:
The study is divided into two parts. The first part focuses on evaluating the safety and tolerability of DS-3939a, meaning researchers want to understand how the body handles the medication and whether it causes any harmful side effects. The second part continues to monitor safety while also measuring how effective the treatment is at a recommended dose. This includes looking at the objective response rate, which measures how many patients experience tumor shrinkage or disappearance after treatment.
Throughout the trial, you will be closely monitored with regular check-ups, laboratory tests, electrocardiograms to check your heart, vital signs measurements, and physical examinations. Imaging studies will track how your cancer responds to the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. The trial is expected to end by July 2027.
Investigational drug:
DS-3939a is a new experimental medication being tested for treating advanced solid tumors. It works by targeting specific pathways that cancer cells use to grow and spread, although the exact mechanism is still under investigation. The medication is administered as an injection in a clinical setting by healthcare professionals. DS-3939a is not yet approved for general medical use and is currently being studied to assess both its safety and effectiveness.
Summary
There is currently one active clinical trial available for patients with recurrent pancreatic carcinoma. This trial is being conducted in three European countries: Belgium, France, and Spain. The study focuses on testing DS-3939a, an experimental intravenous medication designed to treat advanced and metastatic solid tumors. The trial is structured in two phases, with the first phase focusing on safety and tolerability, and the second phase evaluating treatment effectiveness. Patients interested in participating must have measurable disease, adequate organ function, and good performance status. This trial represents an opportunity for patients with recurrent disease who have experienced progression on previous treatments to access a new investigational therapy.